Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
26 Febrero 2020 - 6:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics intended to treat serious and rare diseases, today
announced that senior management will participate in two upcoming
healthcare investor conferences.
Conference Presentation Details:
Event: Cowen & Co. 40th Annual Health Care Conference
Date/Time: Monday, March 2, 2020 at 2:50 p.m. ET
Location: Boston, MA
Event: Barclays Global Healthcare Conference
Date/Time: Tuesday, March 10, 2020 at 4:20 p.m. ET
Location: Miami, FL
Live webcasts for the Cowen & Co. and Barclays conference
analyst-moderated fireside chats may be accessed on the Investors
& Media page of the Company's website at
www.acceleronpharma.com. A replay of each webcast will be available
approximately two hours after the event on the Acceleron
website.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, pulmonary, and neuromuscular diseases. In hematology,
Acceleron and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is developing sotatercept
for the treatment of pulmonary arterial hypertension, having
recently reported positive topline results of the Phase 2 PULSAR
trial and actively enrolling patients in the Phase 2 SPECTRA trial.
The company is also advancing its neuromuscular program with
ACE-083, a locally-acting Myostatin+ agent in Phase 2 development
in Charcot-Marie-Tooth disease.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200226005261/en/
Acceleron Pharma Inc. Investors: Todd James, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations
or
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024